Evidence map›Paper›PMID 35158751›Full record

ReviewCancers2022

Dissection of the MKK3 Functions in Human Cancer: A Double-Edged Sword?

Valentina Piastra, Angelina Pranteda, Gianluca Bossi

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Valentina PiastraOncogenomic and Epigenetic Unit, Department of Diagnostic Research and Technological Innovation, IRCC-Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy.ORCID 0000-0002-9427-2239
Angelina PrantedaOncogenomic and Epigenetic Unit, Department of Diagnostic Research and Technological Innovation, IRCC-Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy.ORCID 0000-0001-7351-6348
Gianluca BossiOncogenomic and Epigenetic Unit, Department of Diagnostic Research and Technological Innovation, IRCC-Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy.ORCID 0000-0002-2947-1063

Funding

Italian Association for Cancer Research 18449Lega Italiana per la Lotta Contro i tumori IG-2019
6 · The paper itself

Abstract

The role played by MKK3 in human cancer is controversial. MKK3 is an evolutionarily conserved protein kinase that activates in response to a variety of stimuli. Phosphorylates, specifically the p38MAPK family proteins, contribute to the regulation of a plethora of cellular processes such as proliferation, differentiation, apoptosis, invasion, and cell migration. Genes in carcinogenesis are classified as oncogenes and tumor suppressors; however, a clear distinction is not always easily made as it depends on the cell context and tissue specificity. The aim of this study is the examination of the potential contribution of MKK3 in cancer through a systematic analysis of the recent literature. The overall results reveal a complex scenario of MKK3's involvement in cancer. The oncogenic functions of MKK3 were univocally documented in several solid tumors, such as colorectal, prostate cancer, and melanoma, while its tumor-suppressing functions were described in glioblastoma and gastric cancer. Furthermore, a dual role of MKK3 as an oncogene as well as tumor a suppressor has been described in breast, cervical, ovarian, liver, esophageal, and lung cancer. However, overall, more evidence points to its role as an oncogene in these diseases. This review indicates that the oncogenic and tumor-suppressing roles of MKK3 are strictly dependent on the tumor type and further suggests that MKK3 could represent an efficient putative molecular target that requires contextualization within a specific tumor type in order to adequately evaluate its potential effectiveness in designing novel anticancer therapies.

Indexed as

cancerMKK3oncogenep38 MAPKtarget therapytherapeutic treatmentstumor suppressor

Identifiers

PMID35158751
PMCPMC8833818
OpenAlexW4205700193

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.